Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases by Dobó, József et al.
August 2018 | Volume 9 | Article 18511
Review
published: 08 August 2018
doi: 10.3389/fimmu.2018.01851
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Nicole Thielens, 
UMR5075 Institut de Biologie 
Structurale (IBS), France
Reviewed by: 
Cordula M. Stover, 
University of Leicester, 
United Kingdom  
Maciej Cedzynski, 
Institute for Medical Biology 
(PAN), Poland  
Christian Drouet, 
Université Grenoble Alpes, France
*Correspondence:
Péter Gál  
gal.peter@ttk.mta.hu
Specialty section: 
This article was submitted to 
Molecular Innate Immunity, 
a section of the journal 
Frontiers in Immunology
Received: 29 May 2018
Accepted: 26 July 2018
Published: 08 August 2018
Citation: 
Dobó J, Kocsis A and Gál P 
(2018) Be on Target: Strategies 
of Targeting Alternative and 
Lectin Pathway Components in 
Complement-Mediated Diseases. 
Front. Immunol. 9:1851. 
doi: 10.3389/fimmu.2018.01851
Be on Target: Strategies of Targeting 
Alternative and Lectin Pathway 
Components in Complement-
Mediated Diseases
József Dobó, Andrea Kocsis and Péter Gál*
Institute of Enzymology, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary
The complement system has moved into the focus of drug development efforts in the 
last decade, since its inappropriate or uncontrolled activation has been recognized in 
many diseases. Some of them are primarily complement-mediated rare diseases, such 
as paroxysmal nocturnal hemoglobinuria, C3 glomerulonephritis, and atypical hemolytic 
uremic syndrome. Complement also plays a role in various multifactorial diseases that 
affect millions of people worldwide, such as ischemia reperfusion injury (myocardial 
infarction, stroke), age-related macular degeneration, and several neurodegenerative 
disorders. In this review, we summarize the potential advantages of targeting various 
complement proteins with special emphasis on the components of the lectin (LP) and 
the alternative pathways (AP). The serine proteases (MASP-1/2/3, factor D, factor B), 
which are responsible for the activation of the cascade, are straightforward targets of 
inhibition, but the pattern recognition molecules (mannose-binding lectin, other collectins, 
and ficolins), the regulatory components (factor H, factor I, properdin), and C3 are also 
subjects of drug development. Recent discoveries about cross-talks between the LP 
and AP offer new approaches for clinical intervention. Mannan-binding lectin-associated 
serine proteases (MASPs) are not just responsible for LP activation, but they are also 
indispensable for efficient AP activation. Activated MASP-3 has recently been shown to 
be the enzyme that continuously supplies factor D (FD) for the AP by cleaving pro-factor 
D (pro-FD). In this aspect, MASP-3 emerges as a novel feasible target for the regulation 
of AP activity. MASP-1 was shown to be required for AP activity on various surfaces, first 
of all on LPS of Gram-negative bacteria.
Keywords: complement system, lectin pathway, alternative pathway, complement inhibitors, complement-related 
diseases
Abbreviations: 3MC syndrome, Malpuech–Michels–Mingarelli–Carnevale syndrome; aHUS, atypical hemolytic uremic 
syndrome; AMD, age-related macular degeneration; AP, alternative pathway; C4BP, C4b-binding protein; CARPA, complement 
activation-related pseudoallergy; CCP, complement control protein; CP, classical pathway; CNS, central nervous system; CR1, 
complement receptor 1; CR2, complement receptor 2; CRP, C-reactive protein; CUB, C1r/C1s, the sea urchin protein Uegf, and 
the human bone morphogenetic protein 1; CVF, cobra venom factor; EGF, epidermal growth factor; DAF, decay-accelerating 
factor; DAMP, damage-associated molecular pattern; FHL, FH-like protein; FHR, FH-related protein; FIMAC, FI membrane 
attack complex; GPI, glycosyl phosphatidylinositol; HAE, hereditary angioedema; HUVEC, human umbilical vein endothelial 
cell; LDLr, low-density lipoprotein receptor; LP, lectin pathway; MAC, membrane attack complex; MBL, mannose-binding 
lectin; MASP, MBL-associated serine protease; MCP, membrane cofactor protein; IGFBP-5, insulin-like growth factor-binding 
protein 5; IRI, ischemia–reperfusion injury; LPS, lipopolysaccharide; PAMP, pathogen-associated molecular pattern; PNH, 
paroxysmal nocturnal hemoglobinuria; PRM, pattern recognition molecule; SIRS, systemic inflammatory response syndrome; 
SP domain, serine protease domain; SLE, systemic lupus erythematosus; TAFI, thrombin-activatable fibrinolysis inhibitor; TSR, 
thrombospondin type repeat; TCC, terminal complement complex; VWA, Von Willebrand factor type-A.
FiGURe 1 | Overview of the complement system. The components of all activation phases are listed in gray boxes, while their inhibitors in green boxes nearby. 
Serine proteases are indicated by red letters. Black arrows indicate the direction of the cascade. Certain enzymatic cleavages are emphasized by red arrows.  
The three activation routes merge at the cleavage of C3 highlighted by dark yellow background.
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BRieF OveRview OF THe COMPLeMeNT 
SYSTeM
initiation Phase
The complement system is a sophisticated network of serum pro-
teins (recognition molecules, proteases, modulators, inhibitors) 
as well as cell-surface regulators and receptors that constitute a 
key part of the host defense machinery. The complement system 
is a powerful effector component of the innate immunity and 
a vital modulator of the adaptive immune response (1–3). The 
complement system recognizes, tags, and eliminates microbial 
intruders and other dangerous particles such as immune com-
plexes, damaged, and altered self cells. The complement system 
is inactive (or at least shows a very low basic activity: “tickover”) 
until it is activated by various danger signals. There are three 
canonical pathways through which the complement system can 
be activated: the classical pathway (CP), the lectin (LP), and the 
alternative pathways (AP) (Figure  1). CP and LP have several 
features in common. In both cases, pattern recognition molecules 
(PRMs) bind to the danger-associated structures. The PRMs, 
like the other complement components, are modular proteins, 
consisting of multiple structural domains (Figure 2). C1q, the 
single PRM of the CP binds primarily to immune complexes 
containing IgG or IgM, and to C-reactive protein (CRP) via its 
C-terminal globular domains (4). These globular domains are 
fused to N-terminal collagen-like arms forming the characteristic 
“bunch-of-six-tulips” structure. The structure of the PRMs of the 
LP resembles that of C1q; globular heads and collagen-like arms. 
However, the recognition domains of mannose-binding lectin 
(MBL), other collectins, and ficolins bind to different structures. 
The C-type lectin domains of MBL recognize the carbohydrate 
pattern of the bacterial surfaces. Ficolins (ficolin 1, 2, and 3) 
bind to acetylated compounds, typically to acetylated sugars of 
bacteria, via their fibrinogen-like domains (5). Collectins (CL-
K1 and CL-L1) also recognize sugars and other potential danger 
signals. Unlike C1q, which has the well-established hexamer 
structure, MBL, ficolins, CL-K1, and CL-L1 exist in different 
oligomerization states, from dimer to hexamer; the tetramer 
being the dominant form at least for MBL. These PRMs circulate 
in complex with serine protease (SP) zymogens and monitor 
FiGURe 2 | Domain structures of the complement components discussed in the article. Each domain type is represented by a different symbol listed at the bottom. 
Domain abbreviations are as follows: SP, serine protease; CCP, complement control protein; CUB, complement C1r/C1s, sea urchin Uegf and bone morphogenetic 
protein-1; EGF, epidermal growth factor-like; vWFA, von Willebrand factor type A; FIMAC, factor I/membrane attack complex; CD5, scavenger receptor cysteine-rich 
domain; LDLr, low-density lipoprotein receptor; MG, α-macroglobulin; TED, thioester domain; ANA, anaphylatoxin; LNK, linker; TSR, thrombospondin-type 1 repeat; 
TMD, transmembrane domain; CPD, cytoplasmic domain; CRD, carbohydrate recognition domain.
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continuously for dangerous particles the bloodstream. When 
the PRMs bind to the target surface, the associated SPs become 
activated and initiate a proteolytic cascade system, which ampli-
fies the initial signal tremendously. C1q is associated with two 
C1r and two C1s proteases (the so-called “tetramer”) to form 
the C1 complex of the CP (6). MBL/ficolin-associated serine 
protease 1 and 2 (MASP-1 and MASP-2) are the initial proteases 
of the LP (7, 8). These SPs, together with the third MBL/ficolin-
associated SP (MASP-3) form a protease family with the same 
domain structure (Figure 2) and similar function. The activation 
of the CP and LP results in the formation of the same enzyme 
complex, a C3 convertase (C4b2a) that cleaves C3, the central 
component of the complement system. The first enzymatic step 
in the CP activation is the autoactivation of C1r. Activated C1r 
then cleaves zymogen C1s, which in turn cleaves C4 and C2. In 
the LP, MASP-1 autoactivates first and then cleaves MASP-2 (9). 
MASP-2 is the enzyme of the LP that cleaves C4 (10, 11), while C2 
is cleaved by both MASP-1 and MASP-2. C3 and C4 are closely 
related thioester-containing proteins that form the basis of the 
convertase complexes (12, 13). Their function is to covalently 
attach the convertase to the activation surface and to capture the 
SP components of the enzyme complex. C2 is the SP component 
of the C3 convertase of the CP and LP. Activation of the AP is 
quite different from that of the CP and LP (14). When the CP/LP 
C3 convertase (C4b2a) cleaves C3, a smaller fragment is released 
(C3a). The larger fragment (C3b) covalently binds to the activa-
tion surface preferably through an ester or, less likely, through 
an amide bond due to the reaction of the exposed thioester bond 
(15, 16). The nascent C3b component binds factor B (FB), the SP 
component of the AP C3 convertase. FB is cleaved by FD, a SP 
which circulates predominantly in its cleaved form in the blood. 
The resulting C3bBb is the AP C3 convertase, which converts 
more C3 into C3b. The new C3b molecules serve as platforms 
for new C3 convertase complexes. In this way, a positive feedback 
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loop amplifies the initial signal tremendously generated either by 
the CP or the LP (17). According to the C3 tickover hypothesis, 
the AP can also initiate on its own without involvement of CP 
or LP (18). The circulating C3 molecules hydrolyze slowly and 
spontaneously in the bloodstream. The resulting C3(H2O) is a 
C3b-like molecule; it can bind FB and then form an “initiation” 
C3 convertase (C3(H2O)Bb). If this fluid-phase C3 convertase 
emerges near a surface, the nascent C3b molecules can bind to 
the surface and initiate the positive feedback loop. In this way, 
the AP continuously monitors the different surfaces and if it finds 
an activator surface, it launches efficient complement activation. 
The self-tissues are protected from AP-mediated damage by 
cell-bound and fluid-phase inhibitors (Figure 1). These inhibi-
tors dissociate the C3bBb complex and serve as cofactors for 
the serine protease factor I (FI) in the degradation of C3b (19). 
Decay-accelerating factor (DAF, CD55), membrane cofactor 
protein (MCP) (CD46), complement receptor 1 (CR1, CD35) 
are cell-surface-bound while the master regulator of the AP is 
the fluid-phase protein, factor H (FH). FH binds to cell-surface-
deposited C3b and facilitates its degradation to iC3b, C3c, and 
C3dg by FI. On endogenous cell membranes, which expose sialic 
acid, binding of FH is tight and the degradation of C3b is rapid, 
while on the so-called “protected surfaces” (e.g., bacteria, fungi) 
binding is weak and the amplification loop of AP can build up. 
There is a positive regulator of the AP, properdin, which increases 
the half-life of the C3bBb complex. Originally, at its discovery, 
properdin was regarded as a pattern recognition-like initiator 
molecule of the AP (20). Later, it was considered as a positive 
regulator (21); however, recently, the pattern recognition func-
tion of properdin has been reconsidered (22, 23).
From the Central Phase to the  
Terminal Pathway
The cleavage of C3 by the C3 convertases is the turning point 
of complement activation. At this point, the three activation 
pathways (CP, LP, and AP) merge into a unified terminal pathway 
(Figures 1 and 3). When the density of surface-deposited C3b 
reaches a certain level, the substrate specificity of the C3 con-
vertases switches to cleave the C5 component. The C4b2a(C3b)n 
and C3bBb(C3b)n convertases cleave the C5 component into a 
smaller (C5a) and larger (C5b) fragments. The C5a fragment, like 
the C3a fragment, is an anaphylatoxin. The anaphylatoxins bind to 
their receptors (C3aR and C5aR1/2) on leukocytes and endothe-
lial cells and initiate inflammatory reactions (24). Structurally, 
C5 is similar to C3 and C4 (although it does not contain thioester 
bond) (25). The cleavage of C5 is the last enzymatic step in the 
complement cascade. From this point, conformational changes 
drive the formation of a self-organizing protein complex that 
damages the membrane of the attacked cells [membrane attack 
complex (MAC)]. After cleavage, the nascent C5b undergoes 
a conformational change that enables it to bind the C6 and C7 
components (26). The resulting C5b–C7 complex binds to the 
cell membrane and captures C8. After conformational changes, 
C8 integrates into the membrane and pave the way to the integra-
tion of multiple copies of C9 molecules. The C9 molecules form 
a pore in the membrane, which results in the disintegration and 
destruction of the cell (27).
COMPLeMeNT-MeDiATeD DiSeASeS
The complement system is an extremely effective cell-killing and 
inflammation provoking machinery. To prevent excessive activa-
tion, the complement system is kept under strict control by the 
different inhibitory mechanisms. A delicate equilibrium between 
activation and inhibition is necessary to maintain the inflam-
matory homeostasis in the human body. When this equilibrium 
is disrupted by any reason, the self-tissues can be damaged and 
severe disease conditions can occur. There are many clinical 
disorders in which uncontrolled (or sometimes the insufficient) 
complement activation is involved. Usually, the etiology of these 
diseases is complex, and the unwanted complement activation is 
only one of the pathological factors. However, evidences obtained 
by using various disease models suggest that preventing or inhib-
iting the pathological complement activation can be a promising 
therapeutic approach.
insufficient Complement Activation
Since the complement system provides a first line of defense against 
invading pathogen microorganisms, deficiency of a complement 
component can lead to severe infections. The consequences could 
be more severe during childhood, when the adaptive immune 
system is not developed enough. Deficiency of the initial SPs of 
CP and LP (C1r, C1s, MASP-2) can result in pyogenic infections 
(28). Deficiency of MBL is the most common immunodeficiency 
in humans, affecting approximately 30% of the human population 
(29). It predisposes to recurrent infections in infancy; however, 
it is not a major risk factor in the adult population. Deficiency 
of the alternative and the terminal pathway components can 
severely compromise the defense against Gram-negative bacte-
rial infections (30). Deficiency of properdin or deficiencies in the 
components of MAC are associated with infections of Neisseria 
species causing meningococcal meningitis or sepsis (31–33). 
A very important function of the CP is the continuous removal 
of immune complexes and apoptotic cells. If this pathway is 
compromised in systemic lupus erythematosus (SLE) due to 
deficiency of C1q, or C4, or C1r/s, severe autoimmune reactions 
occur resulting in tissue injury in the kidneys.
excess Complement Activation
The majority of complement-related diseases are associated with 
overwhelming complement activation due to inappropriate con-
trol. The kidney is especially vulnerable for complement-mediated 
attacks. In the case of C3 glomerulopathy, C3 deposition occurs 
in the glomeruli without immunoglobulin deposition (34, 35). C3 
deposition in this case is likely the consequence of uncontrolled AP 
activation. In contrast to that, in the case of membranoprolifera-
tive glomerulonephritis, CP activation elicits C3 deposition, since 
immunoglobulins and C1q are also deposited (36, 37). The IgA 
nephropathy is characterized by deposition of polymeric IgA1, 
which triggers complement activation through the AP and the LP 
(38, 39). Atypical hemolytic uremic syndrome (aHUS) is also a 
complement-related disease, which can lead to end-stage renal failure 
(37, 40). The driving force behind aHUS is the inappropriate AP acti-
vation often due to variants of (41) or autoantibodies against (42) 
FH, the master regulator of the AP. aHUS is a form of thrombotic 
FiGURe 3 | MASP-1 and MASP-3 play roles in the activation of the alternative pathway (AP). The activation process of the AP is divided into several phases, which 
are indicated by differently colored backgrounds. MASP-3 is proved to be the professional activator of pro-factor D in blood, therefore, plays an important role in the 
pre-initiation phase. The physiological activator of zymogen MASP-3 (zym MASP-3) is hitherto undiscovered (shown by the question mark). MASP-1 is indispensable 
for efficient initiation and amplification of the AP on certain surfaces, although the mechanism is yet unknown (shown by dashed arrows). Black arrows represent 
conversion processes, while red arrows stand for enzymatic reactions pointing from the enzyme toward its substrate. The circle-shaped red arrow symbolizes the 
autoactivation of MASP-1.
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microangiopathy accompanied with thrombocytopenia, hemolytic 
anemia, vascular damage, and thrombosis.
Another rare clinical condition associated with uncontrolled 
AP activation is paroxysmal nocturnal hemoglobinuria (PNH) 
(43, 44). In PNH patients, red blood cells are particularly prone 
to complement-mediated lysis due to the lack of two membrane-
bound regulator proteins: DAF (CD55) and CD59. This is the 
consequence of the defect in glycosyl phosphatidylinositol (GPI) 
synthesis in the cells. GPI is responsible for anchoring various 
proteins to the cell membrane including these inhibitors that 
regulate the activation of the AP (CD55) and the formation of 
MAC (CD59).
Age-related macular degeneration (AMD) is a complement-
related disease, which affects a large population (about 100 mil-
lion AMD cases) worldwide. It is the leading cause of blindness 
among the elderly in the developed world (45). Genetic analyses 
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strongly suggest that uncontrolled complement activation, espe-
ci ally that of the AP, plays a major role in the pathogenesis of 
AMD. Genetic variants of FH, C3, FB, FI, and C9 have been 
associated with AMD (46). In the center of the retina of AMD 
patients, the photoreceptor cells are gradually degraded due to 
a chronic inflammation, which manifests in the accumulation of 
immune deposits called drusen underneath the retinal pigment 
epithelium. The drusens (that contain activated complement 
components) compromise the transport of oxygen and nutrients 
to the photoreceptors facilitating their degeneration. Numerous 
attempts have been made to curb the unwanted AP activation in 
the eye with limited success (47). In order to efficiently influence 
complement activation in the eye, we have to reveal its exact 
mechanism, which could be different in the periphery than in 
the bloodstream.
Ischemia–reperfusion injury (IRI) can be considered as a 
severe autoimmune reaction (48), which plays a major role in a 
number of clinical conditions. When the blood flow in an organ 
stops temporarily for any reason, the deprivation of oxygen 
(hypoxia) induces changes in the tissues, which predisposes 
them for complement-mediated attack after reperfusion. The 
affected cells and tissues are recognized by the immune system as 
damaged self [damage-associated molecular pattern (DAMP)], 
and a complex inflammatory reaction is launched, in which 
the complement system plays a decisive role. IRI significantly 
contributes to the tissue damage in the case of myocardial infarc-
tion, stroke, transplant-induced inflammation, and it can cause 
a complication during coronary artery bypass graft surgery. 
Although the exact mechanism of complement activation in case 
of IRI is not fully clarified yet, a number of evidences suggest 
that inhibition of the LP could be therapeutically advantageous 
(49–53).
Artificial materials used in modern medicine, such as poly-
mer plastics and metal alloys, can also activate the complement 
system and trigger inflammation (54). Nanoparticles used as 
contrast agents or drug carriers can also activate the comple-
ment system, sometimes causing a severe adverse reaction, 
called complement activation-related pseudoallergy (55, 56). 
In this type of hypersensitivity reaction, IgE is not involved. 
Liposomal drugs directly activate the complement system lib-
erating C3a and C5a anaphylatoxins, which trigger mast cells 
and basophils.
If the immune system is exposed to an overwhelming amount of 
danger signals [pathogen-associated molecular patterns (PAMPs) 
or DAMPs], a systemic inflammatory reaction can occur, which 
could be more devastating than the original danger source. In the 
case of systemic inflammatory response syndrome, such as sepsis 
or polytrauma, the massive and systemic complement activation 
fuels a vicious cycle of hyperinflammatory events that can results 
in fatal tissue damage (57).
A growing number of evidences indicate that the complement 
system plays an important role in fundamental developmental 
processes. The lack of functional LP components (MASP-3, 
CL-K1, CL-L1) during embryogenesis results in the Malpuech–
Michels–Mingarelli–Carnevale (3MC) syndrome that manifest 
in characteristic craniofacial dysmorphism and multiple other 
anomalies (58, 59). It was shown that an intact CP is essential 
for postnatal brain development. Contribution of C1, C4, and 
C3 was demonstrated to synaptic pruning essential for proper 
neuron circuit formation (60). These complement components 
tag synapses and mediate their elimination during a discrete 
window of postnatal brain development. C1q or C3 deficiency in 
mice results in improper central nervous system (CNS) synapse 
elimination. If these processes, essential during normal brain 
development, are pathologically upregulated during adulthood, 
they can contribute to the development of neurodegenerative 
diseases, such as Alzheimer disease and frontal temporal demen-
tia (61). In addition to that, uncontrolled CP and LP activation 
in the CNS can also contribute to psychiatric disorders such as 
schizophrenia (62, 63).
CROSS-TALK BeTweeN THe AP  
AND THe LP
As described above, there are three canonical activation routes of 
the complement system. It is also obvious that the CP and the LP 
would not work efficiently without the amplification loop pro-
vided by the AP, hence, the three pathways are naturally intercon-
nected. It is also possible that homologous proteins C4 and C3, or 
C2 and FB can substitute each other to a certain degree; at least 
in  vitro experiments indicate a weak cross-reactivity between 
CP/LP an AP C3 convertase components (64). MASP-1 (65) and 
MASP-2 (66) have both been implicated to be able to directly 
cleave C3; however, the physiological relevance of these reactions 
is uncertain. MBL was also shown to be involved in AP activation 
without the requirement of C2, C4, and MASPs (67), but in the 
light of our recent results, the observed effect could be mediated 
by MASP-1 (68). In summary, the involvement of the LP or LP 
components in AP activation has been demonstrated in the lit-
erature before; however, some results still remain controversial. 
In the subsequent two sections, recent discoveries are presented 
regarding the role of MASP-3 during the very early stage of AP 
activation, and the requirement of MASP-1 for AP activation on 
various surfaces.
Active MASP-3 is the Professional  
Pro-FD Maturase in Blood
The first evidence that MASP-1 or MASP-3 might have an essential 
role in AP function came from the group of T. Fujita (69). They 
created MASP1 knock-out mice by replacing the second exon 
(8). Since this region encodes a common part of both MASP-1 
and MASP-3, the final homozygous mouse strain lacked both 
proteins. Surprisingly, these mice had pro-FD in their sera and 
had no AP activity (69). They suggested that MASP-1 acts as an 
essential enzyme for pro-FD maturation. At the time, it seemed 
like a logical assumption to favor MASP-1 over MASP-3 since 
MASP-1 is a more active enzyme in general with a relatively broad 
substrate specificity (70). Later, the same group suggested that 
MASP-3 might be more important than MASP-1 in pro-FD acti-
vation and suggested that even the proenzyme form of MASP-3 
can act as the activator (71).
Subsequent publications questioned the requirement of either 
MASP-1 or MASP-3 for AP activity. In the serum of a 3MC 
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syndrome patient lacking both proteins, functional AP was 
observed (72), and in mice deficient for MASP-1, MASP-3, and 
FH extensive, AP activation was observed, just like in mice defi-
cient for FH only (73).
To clarify the roles of MASPs in pro-FD activation, we set up 
a series of experiments. In vitro all active MASPs were shown 
to be able to cleave pro-FD efficiently to produce FD, whereas 
the MASP zymogens lacked such activity (74). We prepared 
fluorescently labeled pro-FD, added it to different types of human 
plasma and serum preparations and followed the conversion of 
pro-FD to FD. Pro-FD was efficiently cleaved in all types of blood 
preparations, even in citrated and EDTA plasma, where neither 
the complement nor the coagulation cascade is expected to be 
activated. This experiment established that at least one protease 
is present in normal human blood capable of converting pro-D to 
FD without the prior activation of the abovementioned proteolytic 
cascades. Using a MASP-1-specific and a MASP-2-selective 
inhibitor, these two enzymes could be excluded. After adding 
recombinant active catalytic fragments of MASPs to normal 
human plasma samples, the half-life of labeled pro-FD was mark-
edly reduced upon the addition MASP-3, whereas the other two 
enzymes had no effect (74).
The final “killer” experiment that established MASP-3 as the 
professional (near exclusive) activator of pro-FD came using a 
MASP-3 specific inhibitor, TFMI-3 (75). TFMI-3 blocked the 
conversion of labeled pro-FD to FD in citrated plasma, EDTA 
plasma, and hirudin plasma completely, while in serum, the half-
life was markedly increased. Another conclusion of our studies 
was that active MASP-3 must be present in the blood, since only 
the activated form of MASP-3 can convert pro-FD to FD. Later, 
we provided direct evidence for the extensive basal-level activa-
tion of MASP-3 in human blood by an unknown mechanism (76). 
Finally, the debate seems to have settled. A recent paper showed 
that in 3MC syndrome patients lacking MASP-3, predominantly 
pro-FD is present in their sera, and moreover, in healthy indi-
viduals, some pro-FD is also present beside the dominant active 
form (77).
The picture is now clear. Under normal circumstances, active 
MASP-3 is present in the blood, which activates pro-FD, therefore, 
continuously supplying active FD for the AP (Figure 3). However, 
MASP-3-deficient individuals are not completely defenseless. At 
least one coagulation enzyme can probably also provide low levels 
of FD for the AP, or when the LP is activated, MASP-1 or MASP-2 
might also contribute. These backup mechanisms also need some 
consideration when targeting MASP-3 to control AP activity, as 
it will be discussed later.
MASP-1 is Required for AP initiation  
on Certain Activating Surfaces
Despite the fact that molecular mechanisms of the complement 
system have been thoroughly examined in the past decades, still 
many questions remained about the early steps of the activa-
tion. MASP-1 as a promiscuous enzyme with broad substrate 
specificity (70) has the potential to replace other SPs or amplify 
enzymatic reactions. It has been reported that MASP-1 is indeed 
involved in biological processes beyond LP or even the comple-
ment system.
Recently, we have found a novel function of MASP-1 in AP 
activation apart from its role in the LP (Figure 3). This func-
tion suggests an unexpected linkage between the two pathways 
and also highlights the differences between various activation 
surfaces (68). Previously, specific and highly selective small-
protein inhibitors against all MASPs were developed from 
canonical inhibitor scaffolds using the phage-display technique. 
SGMI-1 is a specific MASP-1 inhibitor, whereas SGMI-2 
inhibits MASP-2, and TFMI-3 is a specific inhibitor of MASP-3 
(9, 75). Activation of the AP in  vitro can be carried out on 
ELISA microtiter plates coated by bacterial lipopolysaccharide 
(LPS) or yeast zymosan. These materials serve as models of the 
pathogenic surfaces. In the absence of Ca2+ using Mg2+-EGTA 
buffer, AP activation can be initiated without the involvement 
of CP and LP. Administration of the specific MASP-1 inhibitor, 
SGMI-1 in this system lead to surprising results. The activity 
of the AP was attenuated significantly through the inhibition 
of MASP-1. However, this effect was only seen on the bacterial 
surface represented by LPS, while zymosan-induced AP acti-
vation was not compromised. To rule out the possibility that 
SGMI-1 may impede other SPs, inhibitors of MASP-1 possess-
ing different mode of action were also tested. Anti-MASP-1-SP 
antibody, N-terminal domains of MASP-1 (M1_D1-3) (78), and 
serpin domain of C1 inhibitor resulted in the same, consider-
able reduction of AP activity but only on LPS. The activity of 
AP in MASP-1-depleted serum remarkably decreased on 
LPS-coated surface while on zymosan-coated surface, it was 
only moderately affected. The mechanism of C3b deposition, 
which is followed in our assay, can be divided to initiation and 
amplification phases. Time-course measurement of C3b deposi-
tion in the presence of subsequently added SGMI-1 inhibitor 
indicated that MASP-1 contributes to both phases of C3b gen-
eration. Although we proved unambiguously that MASP-1 has 
an effect on AP activation, there are still many puzzling details 
to be solved. First, we tested the known components of AP as 
possible reaction partners of MASP-1. It was clarified earlier 
that MASP-1 cleaves C3 only at a very low rate (11) and now 
we confirmed that MASP-1 does not react significantly with 
C3b-bound FB. The contribution of FD was also excluded since 
SGMI-1 does not inhibit FD, and MASP-1 is not the physiologi-
cal activator of pro-FD (74). Our results lead to the conclusion 
that the key player of MASP-1-driven AP activation is probably 
not among the core components of the AP.
Differences between the activating surfaces also need fur-
ther investigations since it seems to be likely that AP initiation 
occurs by various mechanisms. Using specific antibodies in the 
ELISA system, neither MASP-1 nor MBL could be detected 
on LPS surface in Mg2+-EGTA buffer (68). MASP-1 may be 
presented by some other PRMs, which do not necessarily 
require Ca2+ for binding (possibly ficolins). Another possible 
scenario is that MASP-1 forms a labile and transient complex 
with its reaction partners. One clue arises from the literature 
that properdin, which stabilizes C3bBb complex, is crucial 
for LPS-induced but not for zymosan-induced AP activation 
(79). Another coincidence is that LPS, rather than zymosan, 
binds FH with high affinity, which enhances the decay of C3 by 
FI activity. The ratio of these factors, which play a role in the 
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regulation of AP, may be influenced by MASP-1 through a yet 
unknown mechanism.
These new findings draw attention to MASP-1 in the promo-
tion of LPS-induced AP and, therefore, its role in the defense 
against Gram-negative bacteria.
COMPONeNTS OF AP AND LP  
AS POTeNTiAL DRUG TARGeTS
Pattern Recognition Molecules
The PRM of the CP and LP recognize danger signals (PAMPs 
and DAMPs) and provide the framework of the initiation multi-
molecular complexes (the C1 complex, MBL–MASP complexes, 
ficolin–MASP complexes). They have similar overall domain 
architecture: N-terminal collagen-like domains and C-terminal 
globular domains. The structure of C1q is different from that 
of the other PRMs, since the basic trimeric subunit of C1q is 
composed of three different polypeptide chains (A, B, and C 
chains), while that of MBL and ficolins consist of only one kind 
of polypeptide chain. In the case of collectins, collectin kidney 1 
(CL-K1) and collectin liver 1 (CL-L1), a heterotrimeric subunit 
was observed in human blood composed of one CL-L1 and 
two CL-K1 polypeptide chains (called CL-LK) (80). Another 
structural difference between C1q and the proteins of the col-
lectin/ficolin family is that the latter contain a short N-terminal 
cysteine-rich region and an α-helical coiled-coil neck region 
between the collagen-like and the globular domains facilitating 
trimerization of the polypeptide chains. The collagen sequences 
(Gly-Xaa-Yaa repeats) are interrupted at one point in C1q and 
MBL generating a flexible kink region that may play an important 
role in binding to the danger patterns and activating the associ-
ated SPs. The PRMs bind the associated SPs in a Ca2+-dependent 
manner. C1q binds the C1s-C1r-C1r-C1s tetramer, while MBL, 
ficolins, and CL-LK bind MASP dimers. It is probable that low 
oligomeric MBL and ficolins bind a single MASP dimer, while 
higher oligomers (pentamers, hexamers) can bind two MASP 
dimers simultaneously (81). There is a cross-interaction between 
the components of the CP and LP; MBL can bind the C1r2s2 
tetramer and C1q can bind the MASP dimers, although with 
reduced affinity compared to the cognate pairs (82). It is unlikely 
that these interactions have a physiological relevance (except 
maybe in deficiencies); however, the existence of these cross-
bindings proves that the interactions are analogous between 
the PRMs and the associated SPs among the components of the 
CP and LP. The binding of MBL and ficolins to their targets is 
Ca2+-dependent. The affinity of a single carbohydrate-binding 
domain to its target sugar is low (Kd in the millimolar range), 
whereas the avidity of the whole oligomeric molecule is high 
with a Kd in the low nanomolar range. It is very likely that the 
PRMs of higher oligomeric state activate the LP more efficiently 
than the low oligomeric PRMs due to the stronger binding to 
both the target surface and to the MASPs (83). The mechanism 
of activation of the C1 and MBL–MASP complexes is not fully 
clarified yet.
Theoretically, if we want to prevent or inhibit improper 
complement activation in a pathological situation PRMs of the 
initiation complexes are ideal targets; since by inhibiting the 
PRMs, we can shut off the entire amplification machinery of the 
complement system at the very first step. There are three pos-
sibilities to inhibit the function of the PRMs: (1) to prevent the 
binding of the PRMs to their target; (2) to prevent the binding of 
the associated SPs to the PRMs; (3) to prevent the conformational 
changes of the PRMs that are necessary for the activation of the 
SPs. Monoclonal antibodies that bind to the globular domains 
of the PRMs can efficiently interfere with the ligand binding. 
Anti-C1q and anti-MBL antibodies were successfully used to 
block the CP and LP activation, respectively (84). An anti-MBL 
monoclonal antibody (3F8) attenuated myocardial IRI in mouse 
expressing human MBL (85).
Anti-C1q antibodies have been recently reported to greatly 
reduce the inflammatory demyelinating lesions in a mouse 
model of neuromyelitis optica (86) and also to attenuate injury 
with a consequent neuroprotective effect in acute Guillain–Barré 
syndrome mouse models (87). A peptide agent (called 2J) was 
selected from a peptide library on the basis of C1q binding (88). 
This peptide was shown to bind to the globular domain of C1q 
and prevented the binding of C1q to IgG. The 2J peptide efficiently 
inhibited CP-mediated C4 and C3 deposition and MAC forma-
tion in vitro. Although this peptide was a promising candidate 
for therapeutic complement inhibition, no further studies were 
reported about its in vivo application.
Another possibility for inhibiting the CP and the LP is to 
disassemble the initiation complexes. In this respect, it is worth 
noting that in in vitro experiments the C1 complex dissociates in 
the absence of Ca2+ (in the presence of EDTA), or at high ionic 
strength (1  M NaCl), whereas in the case of the MBL–MASP 
complexes, both conditions should apply at the same time (89). 
Moreover, C1 inhibitor, which makes covalent complexes with 
the SPs, dislodges C1r and C1s from C1q, while it cannot disas-
semble the MBL–MASP complexes (90). Nevertheless, it was 
shown that there is a dynamic equilibrium between the different 
MBL/ficolin–MASP complexes in human serum, in other words, 
MASPs can migrate between the complexes (91). Recently, it 
was shown that asparaginase, which is used in oncological treat-
ments, inhibits the LP by reducing the amount of MBL–MASP 
complexes, very likely through dissociating the complexes (92). 
In this case, it is an adverse effect of the oncological treatment, but 
it indicates that a similar approach can be feasible in anticomple-
ment therapy. An anti-MASP-2 monoclonal antibody (OMS721, 
Omeros), which binds to a non-catalytic complement control 
protein (CCP) domain of MASP-2, successfully inhibited the LP 
in in vivo experiments, and also it could disassemble the MBL-
MASP-2 complexes.
There is a report about a viral-derived peptide (PIC1), which 
inhibits the classical pathway through binding to the collagen-
like region of C1q in the C1 complex (93). This peptide might 
lock the conformation of C1q and/or displace the tetramer. 
There is no other report in the literature about an agent, which 
can block the conformational change necessary for the proper 
function of the initiation complexes. A deeper understanding 
of the activation mechanism of the C1 and MBL/ficolin–
MASP complexes is needed to harness this possibility in the 
therapy.
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MASP-1
MASP-1 is the most abundant protease of the LP, and it plays 
a central role in complement activation. Its average serum con-
centration is 143 nM (11 µg/mL), which is 24-times higher than 
the serum concentration of MASP-2 (6 nM, 0.4 µg/mL) (94). The 
members of the C1r/C1s/MASP protease family share the same 
domain organization (Figure  2). At the N-terminus, there is a 
CUB domain (initially recognized in C1r/C1s, sea urchin protein 
Uegf, and human bone morphogenetic protein 1), followed by an 
epidermal growth factor-like (EGF) module and a second CUB 
domain. The MASPs are present as dimers in the circulation, 
and the N-terminal CUB1-EGF-CUB2 region is responsible for 
the dimerization. Another important function of this region is 
that it mediates the binding to the PRMs. The CUB and the EGF 
domains bind Ca2+, and both the dimerization and the PRM 
binding are Ca2+-dependent. The C-terminal region, which pos-
sesses the catalytic activity, consists of two CCP domains and a 
SP domain. The SP domain belongs to the chymotrypsin family 
(Family S1, MEROPS) and shows trypsin-like specificity cleaving 
after basic amino acids (Arg, Lys) in the polypeptide chain. The 
two CCP domains have at least two functions: they serve as spac-
ers between the CUB1-EGF-CUB2 region and the SP domain and 
they provide additional binding sites (exosites) for the substrates 
(13). Both functions have essential roles in the activation of the 
PRM–MASP complexes and in the cleavage of the subsequent 
components (C2 and C4).
MASP-1 has multiple roles in the innate immune response. 
Zymogen MASP-1 has a high autoactivation capacity, which 
plays a key role in the activation of the lectin pathway (95). When 
PRM–MASP complexes bind to the activation surface, zymogen 
MASP-1 autoactivates and the active MASP-1 activates zymogen 
MASP-2 (9, 72). In this way, MASP-1 is the initiator protease of the 
LP. Recently, it has been demonstrated that MASP-1 significantly 
contributes to AP activation on LPS surface through an unknown 
mechanism (68). MASP-1 is also capable of activating endothe-
lial cells by cleaving protease-activating receptor 4 (91, 96). 
The activated endothelial cells secrete cytokines (IL-6 and IL-8), 
and these cytokines promote the chemotaxis of neutrophil 
granulocytes (97). Moreover, MASP-1 treatment increased adhe-
sion between neutrophils and endothelial cells by upregulating 
E-selectin expression in human umbilical vein endothelial cells 
(HUVECs) (98). A genome-wide gene expression profiling study 
on HUVECs corroborated the role of MASP-1 in triggering 
inflammation (99). The analysis showed that MASP-1 up- and 
downregulated numerous inflammation-related genes bridging 
complement activation and endothelial-cell-related inflamma-
tory processes. It was also demonstrated that MASP-1 is able to 
cleave high-molecular-weight kininogen and liberate bradykinin 
(100). Bradykinin is a potent vasoactive, pro-inflammatory pep-
tide, which is responsible for the swelling attacks in hereditary 
angioedema (HAE), a disease associated with C1 inhibitor defi-
ciency (101). Uncontrolled activation of MASP-1 may contribute 
to the development of HAE attacks and worsening the symptoms 
of HAE patients. It was also recognized that MASP-1 serves as 
a link between the complement and the coagulation cascades. 
MASP-1 promotes coagulation by activating prothrombin, 
fXIII, and thrombin-activatable fibrinolysis inhibitor (102–104). 
The effect of MASP-1 on blood coagulation was confirmed by 
using a microvascular whole-blood-flow model (105). The physio-
logical relevance of this phenomenon is not quite clear; however, 
it is very likely that the proteolytic activity of MASP-1 contributes 
to pro-inflammatory and pro-thrombotic events facilitating the 
development of thrombotic complications under pathological 
conditions (106). As the above examples highlight, MASP-1 has 
a relatively broad substrate specificity (it has about 10 known 
substrates), which is quite unusual among complement proteases. 
It should be noted, however, that all the known substrates of 
MASP-1 are related to the innate immune response. Evolutionary 
considerations indicate that MASP-1 is an ancient enzyme of 
the complement system compared to the other members of the 
MASP/C1r/C1s family (107). The relaxed substrate specificity of 
MASP-1 is reflected in its 3D structure (70). The substrate-binding 
groove of MASP-1 is broad and accessible resembling that of 
trypsin, rather than those of other early complement proteases. 
The physiological inhibitors of MASP-1 are serpins. C1 inhibi-
tor, and in the presence of heparin antithrombin, attenuate very 
efficiently the activity of MASP-1 (108). Alpha2-macroglubulin, 
a pan-specific protease inhibitor in the blood was suggested to 
inhibit MASP-1 and consequently the LP (109), but this issue is 
controversial (108, 110). Another potential physiological inhibi-
tor of the LP is MAp44 (aka MAP-1), an alternative splice product 
of the MASP1 gene (111, 112). MAp44 contains the CUB1-EGF-
CUB2-CCP1 domains of MASP-1/3 plus a 17 amino-acid-long 
C-terminal peptide. Since MAp44 lacks the SP domain, it does 
not have proteolytic activity to initiate the LP, but it can dimerize 
and bind to the PRMs like the MASPs. MAp44 attenuates LP 
activity by competing with MASP-1 and MASP-2 for the PRMs 
and displacing them from the complexes. Recombinant MAp44 
was shown to protect against myocardial IRI in mouse models, 
preserving cardiac function, decreasing the infarct size, and pre-
venting thrombogenesis (113). Recombinant chimeric inhibitors 
were also designed and constructed by fusing MAp44 and the 
complement regulatory domains (1–5) of FH (114). One of these 
inhibitors showed simultaneous inhibition of the LP and AP.
Theoretically, the SPs are the most druggable targets in the 
complement system (115). The active sites of these enzymes can 
be easily targeted by small-molecule protease inhibitors. The 
main problem with this approach is the lack of specificity, since 
all the complement proteases and also the proteases of the other 
plasma cascade systems contain chymotrypsin-like SP domains 
(Figure 4). A small-molecule SP inhibitor, which blocks the activ-
ity of a particular complement SP, very likely will inhibit other 
complement proteases, as well as proteases of the coagulation, 
fibrinolysis, and kallikrein–kinin systems to some extent. For 
example, nafamostat mesilate (FUT-175 or Futhan) is a powerful 
inhibitor of the complement cascade, but it has a broad specificity. 
It was shown to attenuate renal and myocardial IRI (116, 117), but 
it also attenuates pancreatitis by inhibiting trypsin and other pan-
creatic enzymes (118), and also coagulation by inhibiting throm-
bin and other clotting enzymes (119). To enhance the specificity, 
the number of interactions should be increased between the SP 
and the inhibitor. A promising approach could be the fragment-
based drug discovery, which generates highly specific molecules 
via linking small chemical fragments (Mw < 300 Da) together that 
FiGURe 5 | Structure of factor D (FD) in complex with a selective small-molecule inhibitor. The figure is based on the structure of FD in complex with “inhibitor 6” 
described by Maibaum et al. (120) (PDB entry 5FCK). Inhibitor 6 has multiple polar and hydrophobic interactions with the protein body. It is notable that inhibitor 6 
interacts with the self-inhibited conformation of FD, probably stabilizing FD in this form. Asp177 (blue) of the S1 pocket forms a salt bridge with Arg202 of the 
self-inhibitory loop (red). The catalytic triad is colored magenta. Numbers indicate amino acid positions in mature FD, while numbers in parenthesis reflect the 
traditional chymotrypsinogen numbering. Hydrogen bonds are indicated by yellow dashed lines. (A) FD shown by ribbon representation. (B) FD shown by surface 
representation.
FiGURe 4 | Specific inhibition of proteases requires multiple favorable contacts in a large contact area with an inhibitor. (A) The structure of MASP-1 in complex with 
a specific small-protein inhibitor, SGMI-1 (PDB entry 4DJZ). SGMI-1 was developed by phage-display (122). Amino acid residues in the randomized positions are 
colored magenta (P4, P2, P1′, P2′, P4′) and blue (P1). All amino acid residues in the randomized positions have contacts with the protease body; moreover, SGMI-1 
has other contact areas with MASP-1 in the non-randomized positions as well. (B) The structure of trypsin in complex with a non-specific small-molecule inhibitor 
(123) (PDB entry 3LJJ). The inhibitor is based on benzamidine. A two-headed arrow indicates the movement of the terminal cyclopentane moiety, which has two 
equivalent binding sites.
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bind only weakly on their own to the target. This approach was 
successfully used to develop specific small-molecule inhibitors 
against FD (120) (Figure 5), but there is no report about similar 
molecules against MASPs. Monoclonal antibodies and other 
biologics can also meet the specificity criterion. Highly selective 
MASP inhibitors were developed by the in vitro evolution of the 
interacting loop of canonical SP inhibitors. Sunflower trypsin 
inhibitor (SFTI) is a 14-amino acid-long cyclic peptide, which 
mimics the protease-interacting loop of the inhibitor scaffold 
of the Bowman–Birk inhibitor family. SFMI-1, an LP-selective 
peptide inhibitor was developed by phage-display selection of 
SFTI variants using MASP-1 as target (121). SFMI-1 proved to 
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be a strong MASP-1 inhibitor (Ki = 65 nM), and a weak MASP-2 
inhibitor (Ki = 1,030 nM). In order to further increase the speci-
ficity, a larger inhibitor scaffold was used in the phage-display 
selection. SGPI-2 (S. gregaria protease inhibitor-2) is a single 
domain small-protein inhibitor (35-amino acid-long) belonging 
to the Pacifastin family of canonical inhibitors. After randomiz-
ing six positions in the protease-interacting loop (P4, P2, P1, P1′, 
P2′, and P4′), a highly specific MASP-1 inhibitor (SGMI-1) was 
selected (122) (Figure 4). SGMI-1 inhibits MASP-1 very effec-
tively (Ki = 7 nM), and very selectively. This inhibitor was used 
to clarify the function of MASP-1 in the innate immune response 
using numerous in vitro and ex vivo assays. Although MASP-1 is 
a tempting target to halt unwanted LP activation and to prevent 
various pro-inflammatory processes, no pharmaceutical develop-
ment of a MASP-1 inhibitor has been reported to date.
MASP-2
MASP-2 is the only protease in the LP that can cleave C4. Its 
serum concentration is rather low (6 nM, 0.4 µg/mL), compared 
to the other complement proteases. These characteristics make 
MASP-2 an ideal target to inhibit pathological LP activation.
MASP-2 has identical domain organization with MASP-1 
and MASP-3 (Figure  2). Isolated MASP-2 has a tendency to 
autoactivate in a concentrated solution (11, 124). This autoac-
tivation capacity, however, cannot manifest in normal human 
serum, where the MASP-2 concentration is low, and each 
MASP-2 molecule is surrounded by MASP-1 molecules on 
the target surface. Under these circumstances, MASP-1 is the 
exclusive activator of MASP-2. The autoactivation ability of 
MASP-2 might be important in  situations, where there is no 
MASP-1 present (e.g., MASP-1 deficiency). It should be noted, 
however, that in the serum of a 3MC syndrome patient, where 
there was neither MASP-1 nor MASP-3 present due to a muta-
tion in the MASP1 gene, no LP activity could be detected (72). 
On the other hand, birds lack MASP-1, but have functional LP, 
suggesting that MASP-2 can independently drive LP activation 
(125). In the sera of these animals, however, the autoactivation 
capacity of MASP-2 must be much higher than that of human 
MASP-2 in normal human serum. A recent publication shows 
that MASP-2 can directly cleave C3 in the absence of C4 and/or 
C2 on LP-activating surfaces (66). MASP-2 was also suggested 
to promote fibrin polymerization by cleaving prothrombin (126). 
The MASP2 gene, like the MASP1 gene, has an alternative splice 
product MAp19 (aka sMAP, MAP-2) (127, 128). This truncated 
gene product contains only the CUB1 and EGF domains plus 4 
unique C-terminal residues. Since MAp19 can bind to the PRMs, 
it may regulate LP activity through displacing the MASPs from 
the complexes. Theoretically, the recombinant form of MAp19 
could be suitable to attenuate LP activity, in practice, the larger 
MAp44 was used for this purpose since it binds to the PRMs with 
higher affinity.
The pathological relevance of MASP-2 was demonstrated in 
MASP-2 knock-out mice, where the animals were significantly 
protected against myocardial and gastrointestinal IRI (50). In the 
hearts of MASP-2-deficient mice, the infarct volume was signifi-
cantly smaller than in those of the wild-type animals. Moreover, 
a recent study demonstrated that an inhibitory monoclonal 
anti-MASP-2 antibody successfully attenuated myocardial IRI 
in wild-type mice (129). An anti-MASP-2 antibody, OMS721, 
developed by Omeros Corporation, is under clinical trial for 
treating aHUS (130) and other thrombotic microangiopa-
thies (131), IgA nephropathy, lupus nephritis, membranous 
nephropathy, and C3 glomerulopathy (132). The mechanism of 
the protecting effect of MASP-2 inhibition in these diseases is 
not clear, since AP activation is believed to be the main driver of 
these conditions. Selective canonical inhibitors against MASP-2 
were also selected by phage-display using the SFTI and SGPI 
scaffolds (121, 122). Both inhibitors were highly specific: SFMI-2 
(Ki = 180 nM) and SGMI-2 (Ki = 6 nM) prevented LP activation 
efficiently, while they did not compromise the activity of the 
other two pathways.
MASP-3
MASP-3 was discovered as the third SP component of the LP 
(133). It has the same domain organization (Figure 2) as MASP-1 
and MASP-2, as described above; moreover, the amino acid 
sequence of its first five domains is identical with that of MASP-
1. This feature is the consequence of the fact that MASP-1 and 
MASP-3 are the alternative splice products of the same MASP1 
gene, along with a third protein MAp44 (111, 112). Variants of the 
MASP1 gene, resulting in the loss of the activity of MASP-3, cause 
the 3MC syndrome, characterized by serious craniofacial, genital, 
and often mental defects (58, 59, 134). The results indicate that 
MASP-3 is involved in neural crest cell migration in early embry-
onic development. Interestingly, the same phenotype is observed 
in patients carrying mutations in the COLEC11 gene (58) or the 
COLEC10 gene (135), both encoding LP components CL-K1 
(aka collectin-11) and CL-L1 (aka collectin-10). It is possible that 
MASP-3 is in complex with CL-K1/L1 when it exerts its function 
during embryogenesis, and it is likely that the proteolytic activity 
of MASP-3 plays an important role.
MASP-3 is different from MASP-1 and MASP-2 in several 
ways. MASP-3 does not autoactivate, does not cleave downstream 
LP/CP components, C4 and C2, and the active form has very low 
activity on most synthetic substrates (136). In vitro, it was shown to 
cleave insulin-like growth factor-binding protein 5; however, the 
relevance of this reaction is uncertain (137). It has also no natural 
inhibitor in the blood; therefore, control of its activity is prob-
ably achieved simply by its very restricted substrate specificity. 
MASP-3 is present in the blood as the mixture of the proenzymic 
and the activated forms; moreover, the activated form seems to be 
the more dominant variant (76). In this aspect, it also differs from 
MASP-1 and MASP-2, which are proenzymic. On the other hand, 
in many regards, MASP-3 has similarities to FD, which circulates 
predominantly in the active form, has no natural inhibitor, and 
has very restricted substrate specificity.
The function of MASP-3 in the blood had been mysterious 
until recently. Initially, it was considered simply as a negative reg-
ulator of the LP since it competes with MASP-1 and MASP-2 for 
binding to PRMs (133). This function may still be valid; however, 
now, strong evidences exist that the active form of MASP-3 is the 
primary physiological activator of pro-FD, producing FD, a key 
enzyme of the AP. The story was detailed in a previous section; 
therefore, we jump to the functional consequences of this activity.
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It seems logical that the activity of the AP can be downregulated 
by the inhibition of MASP-3. Inhibition of MASP-3 would result 
in the accumulation of pro-FD in the blood with only very low 
levels of active FD, hence greatly attenuating AP activity. A study 
presented at 16th European Meeting on Complement in Human 
Disease (138) provided a strong evidence for this assumption. 
A single dose of a monoclonal antibody inhibiting the activity of 
MASP-3 suppressed the activity of the AP and shifted the active 
to zymogen ratio of FD toward the proenzyme, pro-FD, both in 
mice and in cynomolgus monkey. So far, two specific inhibitors 
against MASP-3 were developed. One of them is a canonical 
Kunitz-type recombinant protein, which is based on the second 
domain of tissue factor pathway inhibitor (TFPI) and developed 
by phage-display (75). The other is the abovementioned mono-
clonal antibody by Omeros Corporation (138).
What are the potential advantages of MASP-3 inhibition over 
FD inhibition? Inhibition of both proteins is expected to result in 
similar systemic effects in the blood. The plasma concentration of 
both proteins is similar, around 60 nM. This relatively low value is 
attractive for drug development. On the other hand, FD has a very 
high turnover rate. Its half-life in humans is less than 1 h (139). 
The turnover rate of MASP-3 is not yet known, but because of its 
size, it is most certainly lower compared to FD. This could mean 
that a lower daily dose of a drug candidate inhibitor of MASP-3 
would be required compared to a FD inhibitor.
Deficiency in the AP can result in potentially life-threatening 
meningococcal infections, and AP inhibition carries the same 
risk. Another potential benefit of MASP-3 inhibition would be 
that in this case, a pro-FD pool is still available. In case of a bacte-
rial infection, the LP can be activated, and the resulting active 
MASP-1 and MASP-2 molecules could locally convert pro-FD 
to FD, making the AP amplification possible. Nonetheless, this 
mechanism needs experimental validation.
In all, based on MASP-3’s requirement for the maturation 
of pro-FD, MASP-3 presents itself as a good target to attenuate 
the complement system, with several potential benefits over FD 
inhibition.
Factor D
Factor D (FD) is a single domain SP, which circulates in the blood 
predominantly in the active form (77, 140). It is synthesized 
mainly by adipocytes, hence the alternative name adipsin. In 
the 1970s, it was debated whether it is produced as a proenzyme 
or secreted in the active form (140, 141). Since only the active 
form could be isolated from blood (142), it was assumed that 
it might be activated even before secretion (143). Nevertheless, 
at the DNA level, after the signal sequence, an additional 5 to 7 
amino acid long propeptide is encoded. Now the consensus is that 
active MASP-3 converts the pro from of FD to the active form 
constitutively (74, 75, 77).
Although it is an active SP, FD has an extremely restricted 
substrate specificity. It has very low activity toward synthetic 
substrates, basically, it cleaves only certain thioester compounds; 
however, its natural substrate, FB in complex with C3b or C3b-
like molecules, is cleaved very efficiently (144). The free enzyme’s 
very low activity is due to a unique self-inhibitory loop (145), 
which is displaced when FD binds to C3bB (146).
It has a relatively low mass concentration of 1–4  µg/mL in 
humans (147–149), which in combination with early reports 
showing that FD is the bottleneck of AP activity (140), led to the 
assumption that FD could be the best target to achieve AP inhibi-
tion. However, FD is a small protein of only 25 kDa, so, its molar 
concentration of 40–160  nM combined with its high turnover 
(139) suggest that high daily doses of a FD inhibitor would be 
required to achieve complete sustained inhibition. Recent results 
also suggest that FD may not even be the bottleneck of AP activity. 
In the serum of FD-deficient mice, the addition of FD correspond-
ing to only about 1–2% of the normal FD level was sufficient for 
normal AP activity in vitro (147). In a 3MC syndrome patient, 
whose serum contained mostly pro-FD, some AP activity was still 
present (72), although lower than the normal level (134). These 
data together suggest that even if a potent and specific inhibitor 
is used, at least equimolar amount is required for AP inhibition, 
and even higher doses are necessary for sustained inhibition. 
A study with lampalizumab, a humanized monoclonal anti-FD 
IgG Fab fragment, showed similar observations (150).
One must also consider that, at least in vitro, plasma kal-
likrein was shown to be able to cleave the C3bB pro-convertase 
(151), hence a residual, low-level AP activity might still be 
present even during complete FD inhibition, or FD deficiency; 
however, the in vivo relevance of this cleavage needs further 
validation.
Nevertheless, FD remains a prime target within the comple-
ment system. Several FD inhibitor molecules are under develop-
ment, or in the clinical trial phase (152, 153) for PNH, aHUS, 
and AMD. Achillion developed several small molecule FD 
inhibitors that may be orally administered. A dose of 200 mg/kg 
of ACH-4471 per every 12 h resulted in complete AP inhibition 
in primates (154). An example of the combination of structure-
based and fragment-based drug development targeting FD was 
published recently. Modifying the structure of a small-molecule 
kallikrein inhibitor several compounds were developed that 
selectively inhibit FD (120). Figure 5 shows FD in complex with 
one of the compounds as an example.
Near complete inhibition of FD is expected to have a similar 
outcome as inhibition of MASP-3. Neisserial infection or other 
bacterial infections constitute a possible threat, which requires 
prophylactic treatment or treatment with antibiotics. This is actu-
ally valid for nearly all kinds of anticomplement drugs.
Factor B
Factor B (FB), a five-domain, 90 kDa glycoprotein, is composed 
of three CCP modules, a short connecting segment, a von 
Willebrand factor type A (vWFA) domain, and an SP domain 
(Figure 2). It circulates as a proenzyme, and its activation site 
(Arg234-Lys235) is hindered in the free enzyme from the cleavage 
by FD. FB can form a complex with C3b, or C3b-like molecules, 
to generate the AP pro-convertase, C3bB. The pro-convertase 
probably exists in two, closed and open conformations, in the 
latter, FB being accessible for FD cleavage (155). The FD-C3bB 
interaction facilitates both a shift toward the open conformation 
of C3bB, and a structural rearrangement in FD displacing its 
self-inhibitory loop (146). FD cleaves FB in the pro-convertase 
to release the Ba fragment. The other fragment, the catalytic 
FiGURe 6 | C3c in complex with a compstatin analog. Compstatin, a cyclic 
peptide, was developed by phage-display. Since its discovery, several 
modified compstatin analogs have been developed. Compstatin and its 
analogs bind to C3, C3b, or C3c between the MG4 and MG5 domains. 
Compstatin sterically prevents the C3-convertase (C3bBb) to access its 
substrate C3. The depicted structure was determined using the Ac-V4W/
H9A-NH2 variant of the original peptide. The figure was prepared based on 
the structure by Janssen et al. (170) (PDB entry 2QKI). On the left, the whole 
structure is shown with C3c (brown) in surface representation and compstatin 
(magenta) with spheres. On the right, a close-up of the binding site is shown 
with compstatin represented by sticks. Hydrogen bonds are indicated by 
yellow dashed lines.
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Bb itself is still just a marginally active enzyme (156), it has full 
activity only as part of labile C3bBb complex (157). Once Bb 
dissociates from the convertase complex, it cannot re-associate 
with C3b (157).
FB is absolutely essential for the AP; therefore, it is a prime 
target for AP inhibition, but because of its high concentration 
(about 200–250 µg/mL, or 2–3 µM), it might not seem to be ideal 
at first sight. On the other hand, in order to prevent AP activa-
tion, only the newly formed C3bBb complexes may have to be 
inhibited. Using a potent inhibitor with low Kd toward C3bBb 
could completely block the amplification phase, thereby halting 
the activation process. While C3bBb might be a difficult target for 
testing small-molecule inhibitors, because of the transient nature 
of this complex, the cobra venom factor (CVF)-Bb complex is 
more stable; therefore, it presents itself as a viable target for the 
development of such molecules. It is also notable that at high pH 
(proenzymic), FB alone has significant, easily detectable activity 
toward C3 and certain para-nitroanilide substrates (158). Several 
substrate-analog aldehyde FB inhibitors were developed along 
the way (158).
Inhibitory antibodies might be more easily obtained. They 
only need to prevent access to C3, the very large substrate of 
C3bBb, which is attainable by a bulky antibody molecule binding 
near the catalytic site. However, it is possible that such antibody 
would also bind to free FB; therefore, higher doses might be 
required. Optimally, a small-molecule inhibitor or an inhibitory 
antibody should only bind to Bb, or even better only to the C3bBb 
complex, so that a relatively low dose of the molecule be sufficient 
for complement inhibition. A blocking antibody, binding to free 
FB, which prevents the formation of the pro-convertase complex, 
is also a feasible option. In this case, also high doses would be 
required for optimal effect.
A set of small-molecule inhibitors are under development by 
Novartis against FB (CVF-Bb) for indications such as AMD and 
other complement-mediated diseases (159, 160). Neutralizing 
monoclonal antibodies against Bb by Novelmed Therapeutics are 
under development for various indications (161, 162). A mono-
clonal antibody to mouse FB has been shown to be protective 
in a mouse model of renal IRI (163). Other approaches using 
antisense oligonucleotides (164), or a phage-display selected 
cyclopeptides (165) are other feasible options to control AP 
activation through FB.
While FB is a promising target, so far, no therapeutic agent hit 
the market, or is in the advanced state in clinical trials. As with FD 
or MASP-3 inhibitors, bacterial infections manifest a potential 
risk when patients are treated with FB inhibitors.
C3 and CvF
C3 is the central molecule of complement; the three activa-
tion routes are merged at the generation of C3b and continue 
together as the terminal phase (Figures 1 and 3). C3 circulates 
in the serum at high concentration (4–7 µM; 0.75–1.35 mg/mL). 
Native C3 is a 185 kDa protein containing 13 domains (Figure 2). 
C3 is composed of two chains, α and β. The core is built up of 8 
domains belonging to the α2-macroglobulin family. The thioester 
domain carries a buried thioester bond, which is prone to suffer 
hydrolysis or other nucleophilic attack.
Primary C3 deficiencies were described in a few families over 
the world. Mutation in C3 gene caused impaired C3 synthesis or 
secretion, which produced a low C3 level in the blood. These indi-
viduals are extremely susceptible to recurrent pyogenic bacterial 
infections, especially to Gram-negative but also to Gram-positive 
bacteria (166). Moreover, C3 deficiency impairs maturation of 
immune cells (dendritic cells, memory B  cells, certain T  cells) 
(166, 167). Furthermore, SLE and various renal diseases were 
also observed; however, their mechanism is not fully understood. 
Secondary C3 deficiency is due to malfunctioning of the comple-
ment regulatory proteins, typically FI and FH (168).
Complement activation can be blocked completely at the level 
of C3. On the other hand, C3 is the most abundant protein in the 
complement cascade; therefore, a large amount of an inhibitor 
would be needed to achieve a substantial effect. Compstatin, a 
promising complement-based therapeutic agent, was developed 
against C3 by phage-display using naïve library in 1996 (169). 
Compstatin is a cyclic peptide of 13 amino acids with a single 
disulfide bond. It blocks the access of the convertase to C3 
through steric hindrance. Crystal structure with C3c showed 
that compstatin forms expansive H-bonds with its partner 
(170) (Figure 6). Neither complement regulator proteins nor 
other structurally related proteins (C4, C5) bind compstatin. 
In the past 20 years, the compstatin family has been constantly 
developed. New generations of compstatin analogs possess better 
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pharmacokinetic and pharmacodynamic features. Compstatin 
derivatives were investigated in many complement-related 
animal diseases models and showed promising results (171). Just 
to mention a few, compstatins are efficient in primates in inflam-
matory diseases induced by cardiac surgery, cardiopulmonary 
bypass, or E. coli infection, in treatment of organ transplantation 
to reduce the possibility of xenograft rejection, and in sepsis. One 
of the compstatin derivatives (APL-2) already completed a Phase 
II clinical trial in treatment of AMD by Apellis Pharmaceuticals, 
and another one (AMY-101) started in 2017, the “first-in-human” 
clinical study against PNH by Amyndas Pharmaceuticals. Cer-
tainly, compstatins, as a peptide drug candidates, have their 
limitations especially considering oral administration. The rapid 
proteolytic degradation and poor biocompatibility make drug 
formulation challenging. On the other hand, the high specificity, 
the relatively low cost of production, and high variability gives 
the compstatin family members great potential to become widely 
used, effective, and safe complement therapeutics (171).
There are some other approaches to target complement activa-
tion through C3. Since 1970s, CVF is widely applied to deplete 
complement and to gain knowledge about its role in diseases. 
CVF is a structural and functional analog of C3, forms an AP 
convertase with Bb; however, it is resistant to the activity of 
FI and FH. Since decay of the convertase is abolished, C3 and 
C5 are rapidly exhausted from the blood. Nevertheless, CVF is 
immunogenic; therefore, it can be used only once to avoid anti-
body response. In the last decade, interesting results have been 
published about a chimeric protein, humanized CVF (172). It 
is a C3 derivative obtained by simply replacing the C-terminal 
part with the homologous sequence from CVF. This protein is 
safe and proved to be efficient in various animal disease models 
(AMD, collagen-induced arthritis, PNH, myasthenia gravis, etc.), 
and furthermore, no neutralizing antibody effect was detected in 
mice after prolonged usage (173).
Properdin
The only known positive regulator of the AP is properdin, also 
referred to as factor P. Properdin circulates in the plasma at 
20–125  nM (4–25  µg/mL) concentration as a cyclic polymeric 
glycoprotein. In contrast to most complement proteins, it is 
synthesized primarily by leukocytes and shows different activity 
depending on the type of producing cells. The properdin mono-
mer comprises six complete and one truncated thrombospondin 
type 1 repeat (TSR) domain in tandem connection. The 53 kDa 
monomer is able to form dimers, trimers, and even tetramers in 
a head-to-tail arrangement. Physiologically, the most abundant 
form is the trimer; however, properdin shows tendency to self-
aggregate into higher oligomers under conditions used for its 
preparation. It has an extremely high positive charge, hence it 
tends to bind via ionic interactions to polyanion structures.
Properdin has a significant and well-established role in the AP 
of complement by stabilizing the very labile C3bB and C3bBb 
complexes offering binding sites to C3b, and FB or Bb. Extending 
the half-life of the AP convertase by 5- to 10-fold is essential for the 
effective AP activity (174). Another role of properdin, serving as 
a PRM, was proposed about 10 years ago. A similar function was 
originally suggested by Pillemer, who discovered the “properdin 
pathway.” However, findings of this subject are controversial. 
Caution must be taken since repeated freezing and thawing 
resulted in highly polymerized, therefore, non-physiological, 
aggregated properdin, which binds non-specifically to surfaces. 
Experiments using unfractionated properdin could have led to 
physiologically not relevant observations (175). The binding 
abilities of properdin are also influenced by the contact surface 
and the presence of specific ligands. Experiments in properdin 
knock-out mice demonstrated that in the absence of properdin, 
bacterial LPS- and lipooligosaccharide-induced AP activation 
was absent, while zymosan or CVF-induced activation was only 
partially affected (79). Using compstatin and anti-FP antibody in 
ELISA assays, it has been shown that properdin does not attach 
directly to zymosan or Escherichia coli surfaces, but it contributes 
only to the stabilization of C3bBb complex (176). Recent stud-
ies showed that the binding of properdin to activating surfaces 
is always preceded by deposition of C3b (23), concluding that 
properdin can act as an initiator of AP only in a C3b-dependent 
manner.
Properdin deficiency especially in combination with the lack of 
other complement components (MBL, C2, etc.) causes unequivo-
cal susceptibility to bacterial infections. Disorder in properdin 
and one of the late complement components (C5–C9) increases 
the risk of Neisseria meningitidis infection by 1,000- to 10,000-fold 
(28). Interestingly, the lack of IgG G2m(n) allotype in properdin-
deficient persons also increased the susceptibility to meningo-
coccal disease (177).
Therapeutic application of properdin emerged recently. In 
mouse model, it has been shown that a highly polymerized form 
of recombinant properdin gives protection against N. menin­
gitidis and Streptococcus pneumoniae. A single low-dose treat-
ment was enough to boost complement-activated lysis, which 
significantly reduced bacteremia and increased survival rates 
(178). We should note, however, that the recombinant proper-
din had histidine tag, which could influence its antimicrobial 
activity (179). Newly developed mouse monoclonal antibody 
against properdin was proved to be useful in sandwich-ELISA 
system to determine serum level of properdin in human samples 
(180). This antibody also successfully blocked AP activation in 
human sera.
The lack of properdin can efficiently abolish physiological or 
even unwanted AP activity. Inhibiting the AP through properdin 
can abate the amplification of deposited C3, hereby, the activity of 
the complement cascade. In contrast to C3, properdin is present 
at a relatively low concentration. Consequently, as an important 
regulator of the AP, it may turn out to be a promising therapeutic 
target to block complement activation. Novelmed is developing 
new drug candidates against the components of the AP, which 
do not interfere with the CP, as part of their effors, they evolved 
a new monoclonal antibody against the N-terminal fragment of 
properdin (181).
Factor i
Factor I has an outstanding role in the control of the complement 
system. Along with its cofactors, FI belongs to the regulators of 
complement activation. Although it possesses a low catalytic 
activity on its own, FI can downregulate all activation routes by 
FiGURe 7 | Structure of the complex of C3b, mini factor H (FH), and factor I 
(FI). Mini FH is a potential drug candidate. In vitro, it is more effective than 
full-length FH in accelerating the decay of C3b by FI. The structure shows 
extensive contacts between the three proteins. The figure was made based 
on the structure of ternary complex of C3b-mini FH-FI (S525A) (184) (PDB 
entry 5O32). The colors of the legends match the depicted protein chains. 
The P1 residue (Arg1303) of the primary cleavage site in C3b by FI is indicated 
by sphere representation. Mini FH and the light chain of FI are shown by 
surface representation, whereas C3b and the heavy chain of FI are shown  
by ribbon representation.
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dismantling the central component of the complement cascade: 
C3b (and also C4b). FI contributes to the self-defense of host tis-
sues against complement damage through the acceleration of the 
decay of fluid-phase and surface-bound C3b to iC3b. Degradation 
products of C3b initiate the cellular immune response via their 
interaction with various receptors on immune cells.
FI is an 88  kDa glycoprotein synthesized as a single poly-
peptide chain by hepatocytes. It is a trypsin-like SP consisting 
of five domains; some of them are common in the components 
of the terminal pathway. The heavy chain contains the first 
four domains: FI membrane attack complex domain, CD5-like 
domain, low-density lipoprotein receptor 1 and 2 (LDLr 1 and 2) 
domains, and a small section called d-region with unknown 
homology (Figure 2). The light chain, which is attached to the 
heavy chain by a disulfide bond consists of the catalytically active 
SP domain.
FI has several unusual characteristics: it circulates as an 
“active” enzyme in the blood and does not have an inhibitor (19). 
These and some other features of FI resemble that of two other 
proteases of complement, Factor D (182) and MASP-3. FI has 
an extremely low catalytic activity toward synthetic substrates 
and also toward free C3b and C4b. In order to cleave C3b and 
C4b efficiently, FI needs cofactors. C4b-binding protein (C4BP) 
and FH are soluble cofactors of FI, while MCP (CD46) and CR1 
(CD31) are membrane-bound cofactors. Since no natural inhibi-
tor of FI is known, it is regulated by other mechanisms. First of 
all, the type of the substrate and also the type of its cofactor influ-
ences the activity of FI, and also the cleavage site on C3b or C4b 
and their degradation products. Second, structural data has 
proven recently that many crucial loops of the SP domain are 
disordered without the interacting partners (183). As the ternary 
complex of C3b-FH-FI is formed, ligand binding induces stabili-
zation of the SP domain and, therefore, FI obtains full proteolytic 
activity. After the cleavage of the first bond in C3b (Figure 7), 
the substrates rearranges and the second or third cleavage site 
becomes accessible, while the SP domain of FI endures only 
minor movements (184).
According to its important role in complement regulation, the 
absence of FI causes dangerous, even life-threatening conditions. 
Due to the lack of decay acceleration, increased amounts of C3b 
lead to uncontrolled AP activation. The more C3b molecules are 
present, the more C3 convertases are generated, which results in 
the rapid exhaustion of C3 from the plasma. Individuals with FI 
deficiency are prone to suffer from recurring bacterial infections, 
severe kidney diseases, and most of all AMD (185, 186). Recent 
studies show that identifying rare CR1 variants in combination 
with low serum level of FI can enable therapist to find patients, 
who are the most likely candidates to develop AMD (187). FI 
deficiency is often associated with aHUS. Symptoms frequently 
appear in early childhood after a severe infection or in young 
females shortly after pregnancy. Large international cohorts 
have been established to characterize all genetic variants and 
clinical outcomes. The prognosis of FI-associated aHUS is quite 
poor, in half of the cases, end-stage renal failure developed 
rapidly. Treatment with eculizumab, which is the major thera-
peutic for aHUS, resulted in partial remission in patients having 
FI-associated aHUS (188).
Another aspect that makes FI a potential drug candidate is 
the phenomenon of multiple polymorphisms in complement 
components that can affect the delicate balance between activa-
tion and regulation of an individual’s complement system. The 
inherited repertoire of the complement gene variants was dubbed 
complotype (189). Some variant alleles can result a more reactive 
complement, which usually appears in the increased activity of 
C3b feedback cycle. Hyperactive complotypes raise significantly 
the risk of complement-related diseases at later age. Lower serum 
level of FI compared to FH (along with FH-related proteins) is 
advantageous to produce an effect. Moreover, the administration 
of FI in the presence of cofactor CR1 also enhances the conver-
sion of inflammatory product iC3b to C3dg (190). Experimental 
data prove that increasing the amount of FI in serum of different 
complotypes can convert higher-risk to lower-risk activity. The 
extra amount of FI needed is approximately 50% of normal 
level, which would be a useful therapy in such patients (191). 
Comprehensive characterization of the complement regulatory 
genes in patients already suffering from complement-related 
disorders would enhance developments of personal and success-
ful therapies.
TABLe 1 | Potential drug targets of the complement system discussed in this review.
Protein Role in complement activation expected effects of 
inhibition
Potential diseases Type of the drug candidate 
molecules
Reference
C1q Pattern recognition molecule (PRM) 
of the classical pathway (CP)
Blocking the CP Neurodegenerative diseases Antibody, peptide (84, 86–88)
MBL, ficolins PRM of the lectin pathway (LP) Blocking the LP Ischemia–reperfusion injury (IRI) Antibody (84, 85)
MASP-1 LP initiation, boosting the 
alternative pathway (AP)
Attenuation of the LP 
and LPS-driven AP
IRI Protein, small protein (113, 121, 
122)
MASP-2 LP initiation Attenuation of the LP IRI, renal diseases, atypical hemolytic 
uremic syndrome (aHUS)
Antibody, small protein (121, 122, 
129–132)
MASP-3 AP pre-initiation Attenuation of the AP AP-driven diseases Antibody, small protein (75, 138)
FD AP initiation Attenuation of the AP Age-related macular degeneration 
(AMD), renal diseases
Antibody, small molecule (120, 150, 
154)
FB Driving the AP Attenuation of the AP AMD, renal diseases Small molecule, antibody (158–165)
C3/C3b Component of the AP C3 convertase 
and both C5 convertases
Blocking of AP  
and TP
AMD, paroxysmal nocturnal hemoglobinuria 
(PNH), renal diseases, transplantation
Peptide, protein (169, 
171–173)
Properdin AP C3/C5 convertase stabilization Attenuation of the AP AMD, PNH Antibody (160, 181)
FI Regulation of all pathways via 
degradation of C3b and C4b
NA AMD, aHUS Protein (FI for replacement 
therapy)
(191)
FH AP regulation NA AMD, aHUS, transplantation Antibody, proteins (rec. FH 
constructs for replacement therapy)
(192–195)
NA, not applicable, because inhibition of negative regulators is generally not desirable; however, potentiation could be a feasible approach (195).
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Factor H, FH-Like, and FH-Related 
Proteins
Factor H (FH) is the major regulator of the AP. It is a fluid-phase 
molecule; however, it can bind to surface-deposited C3b and 
regulate the AP C3 convertase by several ways. By binding to 
C3b, it can prevent the capture of FB, consequently, the formation 
of the pro-convertase (C3bB). It has also a convertase decay-
accelerating activity by facilitating the irreversible dissociation 
of the C3bBb complex. Probably, the most important function of 
FH is the cofactor activity, which is necessary for the FI-mediated 
cleavage of C3b to iC3b, through which it prevents the build-up 
of the amplification feedback loop of the AP. FH is a glycoprotein 
of 115 kDa and it consists of 20 CCP (aka short consensus repeat 
or sushi) domains (Figure 2). These domains, which are about 
60 residues in length and contain two highly conserved disulfide 
bonds, are widespread among the complement proteins. Many 
complement regulatory proteins, such as FH and the FH-related 
proteins, CR1, CR2, MCP, DAF, C4BP, are composed predomi-
nantly or exclusively of these repeating structural motifs. The 
four N-terminal CCP domains of FH are responsible for the 
convertase decay-accelerating and cofactor activity. The other 
CCP domains take place in the interaction with different ligands. 
The C-terminal CCP 19–20 domains are indispensable for 
binding to self-surface deposited C3b. According to the current 
knowledge, FH recognizes the juxtaposition of C3b and car-
bohydrates containing sialic acid or glycosaminoglycan on the 
surface and binds strongly through the CCP 19–20 domains. The 
other domains may contribute to the binding to several ligands 
(e.g., heparin/CCP 7), but they are not indispensable for the func-
tion of FH. Based on this knowledge, minimal-size FH molecules 
were designed by combining the N- and C-terminal regions. 
Two constructs contain only six domains (CCP1-4 and 19-20) 
(192, 193). These mini FH molecules (Figure  7) showed more 
effective complement inhibition in different assay systems than 
the full-length FH molecule (192). Another, slightly extended 
construct containing CCP1–5 and 18–20 domains effectively 
inhibited complement activation in vivo and reduced abnormal 
glomerular C3 deposition in a FH-deficient mouse model of 
C3 glomerulopathy (194). Recently, a monoclonal anti-FH 
antibody has been found that could inhibit AP activation by 
potentiating FH (195). This potentiating antibody increases 
the affinity of FH for C3b and facilitates the degradation of the 
convertase by FH. There is an alternative splice product of the 
FH gene, which consists of only the CCP1-7 domains plus a 
four-amino-acid long C-terminus (196). This FH-like protein 
1 (FHL-1) has complement-inhibitory activity, and it may have 
important function in the periphery. It is supposed that FHL-1 
is able to penetrate through the Bruch’s membrane beneath the 
retinal pigment epithelial cells in the eye, while FH cannot. In this 
way, FHL-1 may have a crucial role in the protection of retinal 
cells against complement-mediated attack and prevention of the 
development of AMD (197). Besides FH and FHL-1, there are five 
FH-related proteins (FHR) in the human serum. These proteins 
are encoded by separate genes situated next to the FH gene, and 
these genes arouse very probably through partial gene duplica-
tions. These proteins are shorter than FH and usually consist of 
CCP domains homologs to CCP6-9 and CCP18-20 of FH. Since 
the FHRs lack the complement regulatory CCP1-4 domains, their 
physiological relevance was underestimated at the time of their 
discovery (198). Since then, increasing number of evidences have 
been accumulated demonstrating the physiological role of FHRs, 
although this area is still controversial. Since the FHRs contain 
domains sharing high sequence identity with CCP18-20 of FH, 
these proteins can bind to ligands of FH (e.g., C3b, heparin, CRP). 
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However, these molecules cannot efficiently inhibit the AP since 
they lack the N-terminal regulatory domains of FH (CCP1-4).
FHR-1 was reported to enhance, rather than to inhibit 
complement activation through binding to CRP (199). This 
phenomenon could explain the protective effect of FHR-1 defi-
ciency in AMD (200). FHR-4 was able to facilitate AP and CP 
activation by binding to C3b and CRP, respectively (201). FHR-5 
was also shown to promote complement activation by binding to 
pentraxin 3 (PTX3) and extracellular matrix and by enhancing 
C1q deposition (202). It is also possible that FHRs compete with 
FH on the surface of bacteria, thereby compromising the ability of 
the microorganism to evade complement-mediated attack (203). 
It has been demonstrated that FHR-3 acts as a decoy, being captured 
by N. meningitidis cells instead of FH (204). The level of protec-
tion against N. meningitidis infection may depend on the FH/
FHR-3 ratio in the serum. In general, the serum concentration of 
FH and the FHRs, and their affinity to various ligands may be a 
key factor in the fine tuning of complement-mediated opsoniza-
tion and inflammation. If the delicate balance between FH and 
FHRs is disturbed due to genetic variations, or the amount and 
the composition of the ligands changes in the course of a disease 
(infection, oxidative stress), improper complement activation can 
take place resulting in self-tissue damage.
CONCLUDiNG ReMARKS
The complement system was an appealing drug target even in the 
1970s. However, the early drug development efforts failed mainly 
because of two reasons. The first reason was the lack of specificity 
of the anticomplement compounds. At that time, there was no 
technology to design or select highly specific agents against the 
individual complement components. The advance of structure-
based and fragment-based drug design approaches made pos-
sible to generate selective and efficient small-molecule drugs. 
In addition to that, the modern biotechnological methods have 
provided highly specific biologics [monoclonal antibodies, 
recom binant proteins, nucleic-acid aptamers (205, 206), etc.] 
developed for anticomplement therapy. The most successful anti-
complement drug so far, eculizumab, is a monoclonal antibody, 
and many antibodies are in preclinical or clinical phase in the 
pipeline. The second reason, which hindered the introduction 
of anticomplement drugs in the clinical practice in the past, was 
the insufficient knowledge about the mechanism of action of 
complement in both health and disease. In the recent years, the 
mechanism of activation and regulation of the LP and AP has been 
revealed in more detail, and we got insight into the cross-talks 
between the individual pathways inside the complement system 
and also the cross-talks between the complement and other pro-
teolytic cascade systems (e.g., coagulation). New discoveries have 
also been made about the role of complement in the regulation of 
the adaptive immune system. Based on all of the above mentioned 
scientific and technical advances, essentially, all components of 
the LP and AP became targets of drug development (Table 1). 
It is likely that new drugs with more efficiency and less adverse 
effect will be approved for treating complement-related disorders 
in the near future.
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